Holocene Advisors
JAZZ icon

Holocene Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Holocene Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-240,000
Closed -$39.6M – 865
2020
Q4 		$39.6M Buy
240,000
+10,000
+4% +$1.49M 0.25% 134
2020
Q3 		$32.8M Buy
+230,000
New +$28.5M 0.25% 130

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Holocene Advisors's JAZZ Position: Q2 2026 in Review

Holocene Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 78% in Q2 2026, selling an estimated $126M and leaving 160,991 shares worth $38.8M. The position accounts for 0.09% of the portfolio, ranked #220.

Holocene Advisors first reported a position in JAZZ in Q4 2017 and has held it in 14 quarters since. The position peaked at $139M in Q1 2026. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Holocene Advisors held 160,991 shares of Jazz Pharmaceuticals worth $38.8M as of Q2 2026.
  • Holocene Advisors sold 572,914 Jazz Pharmaceuticals shares in Q2 2026, an estimated $126M.
  • Jazz Pharmaceuticals made up 0.09% of Holocene Advisors's portfolio in Q2 2026, its #220 holding.
  • Holocene Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and has held it in 14 quarters since.
  • Holocene Advisors's Jazz Pharmaceuticals position peaked at $139M in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.